HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Dynamins (Dynamin)

A family of high molecular weight GTP phosphohydrolases that play a direct role in vesicle transport. They associate with microtubule bundles (MICROTUBULES) and are believed to produce mechanical force via a process linked to GTP hydrolysis. This enzyme was formerly listed as EC 3.6.1.50.
Also Known As:
Dynamin; Dephosphin; Dynamin K44A; Dynamin, Alanine44 Substituted With Lysine; Dynamin, Mutated Form, K44A; Dynamin, GTPase-Deficient; GTPase Deficient Dynamin; GTPase-Deficient Dynamin
Networked: 825 relevant articles (23 outcomes, 78 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Robinson, Phillip J: 13 articles (01/2022 - 06/2006)
2. McCluskey, Adam: 11 articles (01/2022 - 01/2009)
3. Bitoun, Marc: 8 articles (01/2022 - 06/2006)
4. Reddy, P Hemachandra: 8 articles (01/2022 - 04/2011)
5. Archer, Stephen L: 8 articles (01/2021 - 05/2012)
6. Lenaers, Guy: 8 articles (10/2019 - 11/2005)
7. Reynier, Pascal: 8 articles (10/2019 - 06/2003)
8. Takei, Kohji: 7 articles (01/2022 - 12/2009)
9. Yamada, Hiroshi: 7 articles (01/2022 - 12/2009)
10. Sesaki, Hiromi: 7 articles (08/2020 - 12/2014)

Related Diseases

1. Autosomal Dominant Optic Atrophy (Dominant Optic Atrophy)
2. Mitochondrial Diseases (Mitochondrial Disease)
3. Brain Ischemia (Cerebral Ischemia)
4. Chronic Renal Insufficiency
06/01/2015 - "Pharmacological targeting of actin-dependent dynamin oligomerization ameliorates chronic kidney disease in diverse animal models."
01/01/2019 - "Thus, dynamin is a promising therapeutic target for treating chronic kidney disease. "
01/01/2019 - "Moreover, promoting dynamin oligomerization with Bis-T-23 restores podocyte function and reduces proteinuria in several animal models of chronic kidney disease. "
01/01/2022 - "We have shown that pharmacological activation of GTPase dynamin ameliorates podocyte injury in murine models of chronic kidney diseases by promoting actin polymerization. "
09/26/2022 - "Abbreviation: DN: Diabetic nephropathy; IF: Intermittent fasting; CPT1A: Carnitine palmitoyltransferase 1A; L-FABP: Liver-type fatty acid-binding protein; STZ: Streptozotocin; LDL: Low-density lipoproteins; HIIT: High-intensity interval training; CKD: Chronic kidney disease; ACEI: Angiotensin-converting enzyme inhibitors; ARB: Angiotensin receptor blockers; MDA: Malondialdehyde; mtDNA: Mitochondrial DNA; UCP3: Uncoupling protein-3; MAM: Mitochondria-associated endoplasmic reticulum membrane; PBMCs: Peripheral blood mononuclear cells; ERK1/2: Extracellular signal-regulated kinase 1/2; DRP1: Dynamin-related protein 1; β-HB: β-Hydroxybutyrate; AcAc: Acetoacetate; GEO: Gene Expression Omnibus; NCBI: National Center for Biotechnology Information; mTORC1: Mechanistic target of rapamycin complex 1; HMGCS2: 3-Hydroxy-3-methylglutaryl-CoA synthase 2; GSK3β: Glycogen synthase kinase 3β; AKI: Acute kidney injury; CMA: Chaperone-mediated autophagy; FGF21: Fibroblast growth factor 21."
5. Neoplasms (Cancer)

Related Drugs and Biologics

1. Proteins (Proteins, Gene)
2. GTP Phosphohydrolases (GTPases)
3. PTEN-induced putative kinase
4. N'- (3,4- dihydroxybenzylidene)- 3- hydroxy- 2- naphthahydrazide
5. PPAR gamma
6. Amyloid beta-Peptides
7. Glucose (Dextrose)
8. Oxidopamine (6 Hydroxydopamine)
9. Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)
10. Phytochemicals

Related Therapies and Procedures

1. Therapeutics
2. Induced Hypothermia
3. Drug Therapy (Chemotherapy)
4. Low-Level Light Therapy (LLLT)
5. Electroacupuncture